AstraZeneca to invest $360 million in Irish drug manufacturing site

Crestor

AstraZeneca said on Tuesday it would invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs), or the main components of medicines.

The Anglo-Swedish drugmaker, which completed its $39 billion purchase of rare disease drugs maker Alexion in July, has a large portfolio of treatments for cancer, heart disease, diabetes and a COVID-19 vaccine, with several drugs under trials.

The planned investment in Dublin is expected to support late-stage development and early commercial supply, the company said, adding that the site can be developed further to add treatments such as antibody drug conjugates and oligonucleotides.

Share: